Millipore Sigma Vibrant Logo

344095 Fluvastatin, Sodium Salt - CAS 93957-55-2 - Calbiochem

344095
Voir les Prix & la Disponibilité

Aperçu

Replacement Information

Tableau de caractéristiques principal

CAS #Empirical Formula
93957-55-2C₂₄H₂₅FNNaO₄

Prix & Disponibilité

Référence DisponibilitéConditionnement Qté Prix Quantité
344095-25MG
Récupération des données relatives à la disponibilité...
Disponibilité limitéeDisponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service

      Ampoule plast. 25 mg
      Prix en cours de récupération
      Le prix n'a pas pu être récupéré
      La quantité minimale doit être un multiple de
      Maximum Quantity is
      À la validation de la commande Plus d'informations
      Vous avez sauvegardé ()
       
      Demander le prix
      Description
      OverviewA synthetic HMG-CoA reductase inhibitor (IC50 = 40-100 nM for human liver microsomes) that acts as an anti-hypercholesterolemic agent. Decreases the basal MMP-1 levels in culture media of endothelial cells in a time- and dose-dependent manner. Inhibits the formation of TBA-reactive substances in Fe(II)-supported peroxidation of liposomes (IC50 = 12 µM). Also available as a 10 mM solution in H2O(Cat. No. 344096).
      Catalogue Number344095
      Brand Family Calbiochem®
      Synonyms(±)-(3Rʹ,5Sʹ,6E)-7-[3-(4-Fluorophenyl)-1-isopropylindol-2-yl]-3,5-dihydroxy-6-heptenoate, sodium
      References
      ReferencesYamamoto, A., et al. 2001. J. Pharm. Pharmacol. 53, 227.
      Dansette, P.M., et al. 2000. Exp. Toxicol. Pathol. 52, 145.
      Ikeda, U., et al. 2000. Hypertension 36, 325.
      Levy, R.I., et al. 1993. Circulation 87 (4 Suppl.), III45.
      Tse, F.L.S. et al. 1992. J. Clin. Pharmacol. 32, 630.
      Yuan, J., et al. 1991. Atherosclerosis 87, 147.
      Product Information
      CAS number93957-55-2
      ATP CompetitiveN
      FormLight yellow solid
      Hill FormulaC₂₄H₂₅FNNaO₄
      Chemical formulaC₂₄H₂₅FNNaO₄
      ReversibleN
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetHMG-CoA reductase
      Primary Target IC<sub>50</sub>40-100 nM against HMG-CoA reductase in human liver microsomes
      Purity≥98% by HPLC
      Physicochemical Information
      Cell permeableN
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      RTECSMJ9675050
      Safety Information
      R PhraseR: 62-63

      Possible risk of impaired fertility.
      Possible risk of harm to the unborn child.
      S PhraseS: 22-24/25-36/37/39-45

      Do not breathe dust.
      Avoid contact with skin and eyes.
      Wear suitable protective clothing, gloves and eye/face protection.
      In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Carcinogenic / Teratogenic
      Storage -20°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications

      Documentation

      Fluvastatin, Sodium Salt - CAS 93957-55-2 - Calbiochem FDS

      Titre

      Fiche de données de sécurité des matériaux (FDS) 

      Fluvastatin, Sodium Salt - CAS 93957-55-2 - Calbiochem Certificats d'analyse

      TitreNuméro de lot
      344095

      Références bibliographiques

      Aperçu de la référence bibliographique
      Yamamoto, A., et al. 2001. J. Pharm. Pharmacol. 53, 227.
      Dansette, P.M., et al. 2000. Exp. Toxicol. Pathol. 52, 145.
      Ikeda, U., et al. 2000. Hypertension 36, 325.
      Levy, R.I., et al. 1993. Circulation 87 (4 Suppl.), III45.
      Tse, F.L.S. et al. 1992. J. Clin. Pharmacol. 32, 630.
      Yuan, J., et al. 1991. Atherosclerosis 87, 147.
      Fiche technique

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision10-January-2011 RFH
      Synonyms(±)-(3Rʹ,5Sʹ,6E)-7-[3-(4-Fluorophenyl)-1-isopropylindol-2-yl]-3,5-dihydroxy-6-heptenoate, sodium
      DescriptionA synthetic, competitive inhibitor of HMG-CoA reductase that acts as anti-hypercholesterolemic agent. Unlike Lovastatin (Cat. No. 438185), Mevastatin (Cat. No. 474700), and Simvastatin (Cat. No. 567020), it does not require activation prior to use for in vitro studies. Reduces the basal MMP-1 levels in culture media of endothelial cells in a time- and dose-dependent manner. Fluvastatin is metabolized in the liver, primarily via hydroxylation of the indole ring at the 5- and 6-positions. N-Dealky-lation and b-oxidation of the side-chain also occurs. The hydroxy metabolites are also reported to have some pharmacologic activity.
      FormLight yellow solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number93957-55-2
      RTECSMJ9675050
      Chemical formulaC₂₄H₂₅FNNaO₄
      Structure formulaStructure formula
      Purity≥98% by HPLC
      SolubilityH₂O (30 mg/ml), DMSO, or Methanol
      Storage -20°C
      Protect from light
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Toxicity Carcinogenic / Teratogenic
      Merck USA index14, 4218
      ReferencesYamamoto, A., et al. 2001. J. Pharm. Pharmacol. 53, 227.
      Dansette, P.M., et al. 2000. Exp. Toxicol. Pathol. 52, 145.
      Ikeda, U., et al. 2000. Hypertension 36, 325.
      Levy, R.I., et al. 1993. Circulation 87 (4 Suppl.), III45.
      Tse, F.L.S. et al. 1992. J. Clin. Pharmacol. 32, 630.
      Yuan, J., et al. 1991. Atherosclerosis 87, 147.